Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 04, 2025 Basilea Pharmaceutica Ltd, Allschwil ...
Seeking Alpha

Basilea Pharmaceutica AG (BPMUF) Q2 2025 Earnings Conference Call Transcript

Ladies and gentlemen, welcome to the Basilea Pharmaceutica Half Year Results 2025 Conference Call and Live Webcast. I am Sandra, the Chorus Call operator. [Operator Instructions] The conference is ...
MarketWatch

Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...
Morningstar

Basilea on track with strong 2025 half-year results

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...
Morningstar

Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...

Basilea Pharmaceutica AG: Strong Cresemba (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 04, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to ...